Search results | multiple sclerosis


Multiple Sclerosis Partnering

The Multiple Sclerosis Partnering provides understanding and access to the multiple sclerosis partnering deals and agreements entered into by the worlds leading healthcare companies


Glenmark Pharma sells rights to multiple sclerosis/Crohn’s disease drug to Sanofi

The agreement grants Sanofi (previously Sanofi-Aventis) a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn’s Disease and other inflammatory conditions.

Merger news : Actavis eyes $3 billion bid for Almirall

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Morphosys: Clear leaders in antibody generation

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications.

Current Agreements Deal Analysis Update : July 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Abbvie: M&A activity 2009-2014

Abbvie has acquired only one company in 2010 with the purchase of Facet Biotechnology valued at $722 million.

Acorda Therapeutics: Maintaining an open patient dialogue to treat neurological diseases

Acorda Therapeutics is a commercial stage biopharmaceutical company identifying and developing treatments for neurological disorders including multiple sclerosis, spinal cord injury and disorders of the nervous system. 

Acorda Therapeutics: Partnering activity 2009-2014

Acorda Therapeutics, a leading biotechnology company, aims at improving CNS disorders in patients. With its headquarters in the USA, the big biotech company believes in sharing ideas for innovative medical advances.

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.


Sanofi is a top pharmaceutical company based in Paris, France


Sorry, your search returned no results.


Servier and GeNeuro in GNbAC1 multiple sclerosis deal

GeNeuro has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis

Merck Serono and Fast Forward in collaboration to accelerate development of treatments for multiple sclerosis

Proposals will be jointly developed by Merck Serono and Fast Forward. Merck KGaA will provide up to $19 million in funding.

Ambrx and Merck Serono expand collaboration through ARX424 multiple sclerosis alliance

This second collaboration between the two companies follows a previous agreement announced in 2007 to develop ARX201, Ambrx’s long-acting growth hormone product, currently in Phase II of clinical development.

Merck Serono and Apitope in licensing agreement on novel peptide therapeutics for treatment of multiple sclerosis

Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467.

Receptos in $360 million public offering

Receptos announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share

AstraZeneca, MedImmune strengthen its biotech partnering with UofCambridge

AstraZeneca, MedImmune has entered into four new biotech partnering with the University of Cambridge, building further on their existing partnership.

Rush University Medical Center receives $42 million in royalty financing

DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.

Big pharma, Roche starts a new venture with Inception

Big pharma, Roche said it will partner with Inception Sciences and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis.

National MS Society committees to give $29 million for research financing

The National Multiple Sclerosis Society has committed another $29 million to support an expected 83 new MS research projects and training awards.

Biogen Idec and UCB make a pharma alliance pact

Biogen Idec and UCB have signed exclusive pharma alliance agreements granting UCB the right to commercialize Biogen Idec products.